An­a­lysts write off Di­men­sion’s lead pro­gram af­ter see­ing weak da­ta on he­mo­phil­ia B, shares plunge

Shares of Di­men­sion Ther­a­peu­tics $DMTX were pum­meled on Tues­day, af­ter the biotech post­ed sub­par Fac­tor IX scores on its gene ther­a­py pro­gram for he­mo­phil­ia B.

By the num­bers: Pa­tients in one co­hort tak­ing DTX101 had peak Fac­tor IX (FIX) ex­pres­sion of 13%, 20% and 12% over 4 to 8 weeks, ac­cord­ing to in­ves­ti­ga­tors. At the 12-week fol­lowup, though, the scores had slipped to 5% and 8% in two pa­tients at 12-weeks fol­low-up, and 7% for the third pa­tient at 7 weeks. “For the low-dose co­hort, ex­pres­sion lev­els achieved 10-11% peak ac­tiv­i­ty, sta­bi­liz­ing be­tween 3-4% at last fol­low-up.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.